Oncimmune Regulatory News (ONC)

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Oncimmune Holdings plc ("Oncimmune" or the "Company")

Extension of the deadline for completion of conditions for the Delayed Completion Placing

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces that the deadline for the completion of the conditions on the Delayed Completion Placing, originally announced on the 27 September 2017, has been extended by the parties.

As part of the placing of 4,166,667 Ordinary Shares announced on 27 September 2017, 833,333 Ordinary Shares ("Delayed Completion Placing Shares") were placed conditional on receipt of confirmation from HMRC that they are regarded as a qualifying holding for the purposes of Part 6 of the Income Tax Act 2007 (the "VCT Condition"). Under the original terms of the Placing, the VCT Condition had to be satisfied or waived on or before 8.00 am on 24 November 2017. Due to administrative delays in receiving such confirmation from HMRC, the parties have agreed to extend the deadline for the completion of the VCT Condition until 8.00 am on 31 January 2018.

Admission of the Delayed Completion Placing Shares will occur within five business days of satisfaction of the VCT Condition. An announcement will be made at that time confirming the timing of admission of the Delayed Completion Placing Shares.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@Oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Broker)

Giles Balleny, Hugh Kingsmill Moore

+44 (0) 203 829 5000

 Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com